Reply to: Marketing pitches of ‘magic mushrooms’ and ‘psychedelics’ mask that psychotomimetics use exposes those vulnerable to serious adverse effects

Abstract

Braillon A (2011) The many moral responsibilities of independent datamonitoring committees. Am J Bioeth 11: 16–17. Council for International Organizations of Medical Sciences (1999) Guidelines for preparing core clinical-safety information on drugs second edition – Report of CIOMS working groups III and V. Geneva: Council for International Organizations of Medical Sciences. Huxley A (1961) US State Department-sponsored speech to the Tavistock Group. California Medical School. Morton E, Sakai K, Ashtari A, et al. (2023) Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. J Psychopharmacol 37: 49–60. Naudet F, Fried EI, Cosgrove L, et al. (2022) Psychedelic drugs: More emphasis on safety issues. Nature 611: 449. Tanne JH (2004). Humphry Osmond. BMJ 328: 713.